Topical compositions containing cannabidiol

Abstract

A topical composition comprising an aqueous composition comprising a cannabinoid, particularly cannabidiol, in niosomes having a size of less than 500 nm, and at least one topically acceptable excipient, characterized in that the niosomes comprise (i) at least one linear or branched polyglycerol esterified with a saturated or monounsaturated linear fatty acid, (ii) at least one polysaccharide, and optionally (iii) at least one glycol having 4 to 16 carbon atoms.

Description

[Technical Field]

[0001] The present invention relates to topical compositions comprising cannabinoids. In particular, the present invention relates to topical compositions comprising cannabidiol incorporated into niosomes, preferably niosomes having a size of less than 500 nm, and at least one topically acceptable excipient. [Background technology]

[0002] Cannabis sativa L. is an annual herbaceous plant belonging to the Cannabaceae family, known since ancient times for its industrial and therapeutic uses.

[0003] Cannabis inflorescences (or flos) contain the highest concentrations of cannabinoids, the characteristic and exclusive active substances of the cannabis plant; the two main active substances are delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD).

[0004] Currently, over 500 substances have been isolated from the cannabis plant, including over 120 cannabinoids, such as tetrahydrocannabinol (THC), cannabidiol (CBD), cannabichromene (CBC), cannabigerol (CBG), cannabidivarin (CBDV), and cannabinol (CBN), which are present in varying amounts in the aerial parts of the cannabis plant.

[0005] Cannabis and its derivatives are currently approved for the treatment of many pathological conditions, including chemotherapy-induced vomiting, nausea, and pain, spasticity associated with multiple sclerosis, and some forms of epilepsy (Abrams, DI, European Journal of Internal Medicine, March 2018, Volume 49, Pages 7-11). Delta-9-THC is one of the major cannabinoids in cannabis responsible for its therapeutic effects and uses, but its psychoactive potential and addictive properties have limited its therapeutic development. Cannabidiol (CBD), the other major cannabinoid present in the cannabis plant, differs from Delta-9-THC in that it has no psychotropic, cannabimimetic, or addictive properties (Babalonis et al., Drug Alcohol Depend. 2017 March 01; 172: 9-13). The chemistry and pharmacology of CBD, as well as its molecular targets, have been recently reviewed. Indeed, after a long period of neglect, CBD is now attracting attention for its therapeutic properties, including for skin disorders (Pisanti et al., Cannabidiol: State of the art and new challenges for therapeutic applications, Pharmacology and Therapeutics, Volume 175, July 2017, Pages 133-150).

[0006] Cannabidiol is primarily extracted from the aerial parts of cannabis (Cannabis sativa L.), but is also produced synthetically. Cannabidiol may have beneficial effects on the skin, interacting with the skin's endocannabinoid system, for example, by regulating sebum secretion. Numerous scientific studies have confirmed the regenerative abilities of cannabidiol, which is also useful as an anti-inflammatory, antioxidant, healing, and antibacterial agent for the skin and skin appendages. Cannabidiol can also support natural cell regeneration and act as a protective shield against harmful environmental influences (anti-pollution effect).

[0007] However, cannabidiol is also known to be unsuitable for the preparation of topical formulations, particularly cosmetic and / or medical device and / or pharmaceutical formulations for application to the skin and mucous membranes, due to its poor solubility in water and the resulting instability or incompatibility with the high proportions of water typically present in creams, lotions, gels or other topical formulations. Therefore, cannabidiol is currently used in oily solutions / suspensions that have poor ability to penetrate the skin and epithelia, which inhibits or reduces the effectiveness of topical cannabidiol administration.

[0008] The use of niosomes to improve the solubility and stability of topical cannabidiol formulations and their permeation through the skin has been suggested by E. Ripamonti et al., "Evaluation of the efficacy of proprietary niosomes as enhancers of skin permeability of plant extracts: an in vitro study", H&PC Today, vol. 13(2) March / April 2018, however, the results obtained with the niosome model described in WO2017 / 168354A1 did not produce statistically significant results.

[0009] To date, the cosmetic industry is still searching for compositions that allow for the formulation of cannabidiol for topical application and that can effectively deliver cannabidiol through the skin. Summary of the Invention

[0010] The applicant has been faced with the problem of topical administration of cannabidiol and has surprisingly found a formulation of cannabidiol incorporated into niosomes that is able to overcome the drawbacks known in the art.

[0011] In particular, the applicant is faced with the problem of creating a topical composition comprising cannabidiol in the form of an aqueous emulsion that is stable over time and does not separate and / or precipitate and / or change its components.

[0012] At the same time, the applicant faced the problem of creating a topical composition comprising cannabidiol that is capable of solubilizing higher amounts of cannabidiol.

[0013] Finally, the applicant was faced with the problem of creating a topical composition comprising cannabidiol that improves the penetration of cannabidiol through the skin.

[0014] After extensive experimentation, the Applicant has found that a topical composition comprising a cannabidiol composition incorporated into niosomes comprising at least one linear or branched polyglycerol esterified with a saturated or monounsaturated linear fatty acid, (ii) at least one polysaccharide, preferably a β-glucan, and optionally (iii) at least one glycol having 4 to 16 carbon atoms, preferably caprylyl glycol, makes it possible to solubilize up to 5% by weight or more of cannabidiol and enhances the penetration of cannabidiol through the skin, thereby making more cannabidiol available and more effective for the same amount of product administered.

[0015] In particular, the applicant has found that the compositions of the present invention exhibit increased elasticity, estimated by extrusion measurements, which is aided by the presence of β-glucan, which gives the niosomes improved plasticity and deformability when crossing the intercellular spaces of the skin.

[0016] Applicant has further found that the resulting topical compositions are stable over time, do not cause irritation, and have sufficient microbial resistance.

[0017] Finally, the Applicant has found that the topical composition thus obtained, in addition to providing effective protection from air pollutants, such as particulate matter, was also able to improve skin cell viability and cell nutrition, and to exert significant anti-inflammatory capabilities, which are partly related to the improved penetration of the cannabidiol component and partly related to the presence of β-glucan.

[0018] Additionally, applicants have found that the compositions of the present invention have significant soothing and anti-itch activity in the skin, along with stimulation of mitogenesis in hair bulb cells, while preliminary evaluations, still in progress, suggest that the compositions of the present invention have significant pain-relieving activity in the skin.

[0019] The applicant also believes that the results obtained with cannabidiol can be extended to other cannabinoids, such as the aforementioned cannabigerol (CBG) and cannabinol (CBN), in terms of stability and penetration ability.

[0020] Therefore, a first object of the present invention relates to a topical composition comprising an aqueous composition comprising a cannabinoid, in particular cannabidiol, in niosomes having a size of less than 500 nm, and at least one topically acceptable excipient, characterized in that said niosomes comprise (i) at least one linear or branched polyglycerol esterified with a saturated or monounsaturated linear fatty acid, (ii) at least one polysaccharide, and optionally (iii) at least one glycol having from 4 to 16 carbon atoms.

[0021] A second aspect of the present invention relates to an aqueous composition, in particular an aqueous dispersion or solution, comprising a cannabinoid, in particular cannabidiol, incorporated into niosomes, characterized in that said niosomes comprise (i) at least one linear or branched polyglycerol esterified with a saturated or monounsaturated linear fatty acid, (ii) at least one polysaccharide, and optionally (iii) at least one glycol having from 4 to 16 carbon atoms.

[0022] A third aspect of the present invention relates to a method for preparing an aqueous composition comprising niosomes containing cannabinoids, in particular cannabidiol, comprising the use of hand shaking or ultrasonic shaking techniques, wherein the niosomes comprise (i) at least one linear or branched polyglycerol esterified with a saturated or monounsaturated linear fatty acid, (ii) at least one polysaccharide, and optionally (iii) at least one glycol having from 4 to 16 carbon atoms. [Brief explanation of the drawings]

[0023] The present invention is best explained in the following detailed description, which proceeds with reference to the accompanying drawings, which are provided for illustrative purposes only and are therefore not limiting.

[0024] [Figure 1] 1 shows a micrograph of the niosome-dispersed vesicles (CBD-S5) of Example 1 observed by a TEM transmission electron microscope (JEM-1200EX, JEOL Co., Tokyo, Japan) using the negative staining method. [Figure 2] Figure 1 shows a dynamic light scattering (DSL) graph obtained by analyzing the same sample of niosome dispersion (CBD-S5) as in Example 1 using a Brookhaven 90Plus-Particle Size Analyzer instrument. [Figure 3] FIG. 5 shows a graph of relative cell viability of a reconstituted human epidermis model treated with the niosome dispersion of Example 1 (CBD-S5) versus a positive control (PC) and a negative control (NC), as described in Example 5A. [Figure 4] FIG. 10 shows a graph of relative cell viability of a reconstituted human epidermis model treated with the niosome dispersion of Example 1 (CBD-S5) in the presence or absence of PM2.5, relative to a positive control (PC) and a negative control (NC), as described in Example 8. [Figure 5]1 shows a graph of the relative percentage of IL-1α release of a reconstituted human epidermis model treated with the niosome dispersion of Example 1 (CBD-S5) in the presence or absence of PM2.5, relative to a positive control (PC) and a negative control (NC), as described in Example 8. DETAILED DESCRIPTION OF THE INVENTION

[0025] In a first aspect, the present invention relates to a topical composition comprising an aqueous composition comprising cannabidiol, in particular cannabidiol, incorporated into niosomes having a size of less than 500 nm and at least one topically acceptable excipient, characterized in that the niosomes comprise (i) at least one linear or branched polyglycerol esterified with a saturated or monounsaturated linear fatty acid, (ii) at least one polysaccharide, and optionally (iii) at least one glycol having from 4 to 16 carbon atoms.

[0026] The expression "topically acceptable" as used herein is intended to define a substance that is recognized as having no adverse side effects (irritation, toxicity, etc.) when applied to the skin, epithelia and / or mucous membranes.

[0027] The expression "niosome" or "niosomes" as used herein is intended to define hydrophilic vesicles formed from non-ionic surfactants oriented in bilayers.

[0028] Advantageously, the niosomes used in the present invention have a diameter of less than 400 nm, more preferably less than 300 nm, even more preferably less than 200 nm.

[0029] Preferably, the niosomes used in the present invention have a diameter greater than 10 nm, more preferably greater than 20 nm, even more preferably greater than 40 nm.

[0030] Advantageously, the niosomes used in the present invention have a diameter of between 50 nm and 180 nm, preferably between 70 nm and 150 nm.

[0031] The linear or branched polyglycerols esterified with saturated or monounsaturated straight-chain fatty acids useful in the present invention are obtained by esterifying linear or branched polyglycerols with saturated or monounsaturated straight-chain fatty acids.

[0032] Cannabidiol useful in the present invention may be of natural and / or synthetic origin and preferably has a purity of 95% or greater, 96% or greater, 97% or greater, 98% or greater, or 99% or greater. Advantageously, cannabidiol useful in the present invention has a purity of about 100%.

[0033] Naturally derived cannabidiol may contain small percentages of other cannabinoids, such as cannabichromene, cannabigerol, and cannabinol, generally totaling less than 5%, less than 4%, less than 3%, less than 2%, or less than 1%.

[0034] Preferred examples of polyglycerols are triglycerol, tetraglycerol, hexaglycerol, octaglycerol, decaglycerol. Linear or branched chain polyglycerols useful in the present invention are commercially available.

[0035] Examples of commercially available products are the polyglycerols sold by American International Chemical LLC under the trade name Polyglycerol-3, by Spiga Nord SpA. under the trade names Vegetable Polyglycerine-3, Vegetable Polyglycerine-4, Vegetable Polyglycerine-6, and Vegetable Polyglycerine-10, and by Solvay Chemicals, Inc. under the trade names Polyglycerol-3 and Polyglycerol-4.

[0036] Useful examples of saturated straight-chain fatty acids include monocarboxylic acids having 4 to 32 carbon atoms, such as butyric acid, valeric acid, caproic acid, enanthic acid, caprylic acid, pelargonic acid, capric acid, lauric acid, myristic acid, palmitic acid, margaric acid, stearic acid, arachidic acid, behenic acid, lignoceric acid, cerotic acid, montanic acid, melissic acid, and lacteric acid.

[0037] Preferred saturated straight chain fatty acids include monocarboxylic acids having 12 to 22 carbon atoms, such as lauric acid, myristic acid, palmitic acid, margaric acid, stearic acid, arachidic acid, and behenic acid.

[0038] Useful examples of straight chain monounsaturated fatty acids include monocarboxylic acids having 14 to 24 carbon atoms, such as myristoleic acid, palmitoleic acid, oleic acid, gadoleic acid, and erucic acid.

[0039] Useful examples of mixtures of fatty acids are vegetable oils obtained by pressing or extracting seeds or fruits, such as olive oil, peanut oil, coconut oil, palm oil, and rapeseed oil. Olive oil and coconut oil, especially olive oil, are preferred due to their low content of polyunsaturated acids.

[0040] Esters of linear or branched chain polyglycerol with linear saturated or monounsaturated fatty acids, or mixtures thereof, useful in the present invention are commercially available. Examples of commercially available products are Polyaldo, such as Polyaldo® 6-2-S (polyglyceryl-6 distearate), Polyaldo® 10-1-S (polyglyceryl-10 stearate), Polyaldo® 10-1-O (polyglyceryl-10 oleate), Polyaldo® 10-2-P (polyglyceryl-10 dipalmitate), by Lonza, Hydriol, such as HYDRIOL® PGO (polyglycerol-4-oleate), HYDRIOL® PGD (polyglycerol-3-diisostearate), by Hydrior AG, Germany, Soavirol, such as Soavirol OV6 (olive oil polyglyceryl-6 ester), Soavirol OV4 (olive oil polyglyceryl-4 ester), by Naturalis srl, and Nikko and polyglycerol esters commercially available under the trade names Nikkol Hexaglyn, such as Nikkol Hexaglyn 1-L (polyglyceryl-6 laurate) and Nikkol Hexaglyn PR-15 (polyglyceryl-6 polyricinoleate) by Special Chemicals Co, Ltd. Further suppliers of polyglycerol esters for cosmetic applications can be found at https: / / cosmetics.specialchem.com / selectors?q=polyglvceryl

[0041] The polysaccharides useful in the present invention are preferably selected from the group consisting of naturally occurring polysaccharides such as pullulan, glucan, alginate, amylose, glycogen, inulin, and the like.

[0042] Advantageously, the polysaccharides useful in the present invention are selected from the group consisting of α- and β-glucans, more preferably β-glucans.

[0043] β-Glucans are linear polysaccharides containing glucose molecules linked together by β(1-3) glycosidic bonds. β-Glucans are natural products found in cereals, bacteria, and fungi. Oats and barley are particularly rich in β-glucans, and their production is primarily derived from extraction from these cereals. β-Glucans obtained from fungi are also widely available commercially. β-Glucans derived from fungi and yeast contain branched linkages with glycosidic and β(1-6) bonds, while β-glucans derived from cereals have glycosidic, β(1-3) and β(1-4) bonds. β-Glucans derived from cereals are more soluble in water and are therefore preferred for the purposes of the present invention.

[0044] A particularly useful β-glucan for the purposes of the present invention is the β-glucan sold under the trade name Ohly-GO® Glucan by Ohly GmbH, Germany, under the trade name Chitoglucan® by Maypro Industries LLC, under the trade name Lynside® Wall Glucan by Lesaffre Human Care, and under the trade name Beta Glucan by HerbaKraft Inc. Further suppliers of β-glucans for cosmetic applications can be found at https: / / cosmetics.specialchem.com / inci / beta-glucan

[0045] Glycols having 4 to 16 carbon atoms useful in the present invention are preferably selected from the group consisting of 1,2-butanediol, 1,2-pentanediol, 1,2-hexanediol, 1,2-heptanediol, 1,2-octanediol (caprylyl glycol), 1,2-decanediol (capryl glycol), 1,2-dodecanediol (lauryl glycol), and 1,2-hexadecanediol.

[0046] 1,2-Hexanediol, 1,2-Heptanediol, 1,2-Octanediol (Caprylyl Glycol), 1,2-Decanediol (Caprylyl Glycol) are particularly preferred. For the purposes of the present invention, 1,2-Octanediol (Caprylyl Glycol) is advantageously used.

[0047] Commercially available glycol-containing products useful for the purposes of the present invention are sold by CBW Chemie GmbH, Germany, by Inolex Inc., USA under the trade name Lexgard®, by Wintersun Chemical, USA, and by Chemo's GmbH & Co. KG.

[0048] Suppliers of polyglycerols and their esters, β-glucans, and glycols advantageous in the present invention can be found on the internet, for example, at https: / / www.food-inqredients.com / enqlish / , http: / / www.buversquidechem.com / , and https: / / cosmetics.specialchem.com.

[0049] In the preparation of the niosomes employed for the purposes of the present invention, further components suitable for stabilizing and preserving aqueous solutions / dispersions of niosomes are preferably used, for example water-soluble natural antioxidants such as ascorbic acid and its derivatives, and polyphenols.

[0050] Aqueous compositions containing the niosomes of the present invention can be prepared according to techniques known in the art, for example, by hand shaking techniques or by ultrasonic techniques.

[0051] The hand shaking technique involves a first step of solubilizing the components in a volatile organic solvent, such as ethyl ether, chloroform or methanol, carried out in a glass flask; a second step of evaporation carried out in a rotary evaporator at room temperature (20-25°C), leaving a thin layer of the components adhering to the walls of the flask; and finally a third step of rehydration with an aqueous phase containing the plant extract at a temperature between 0°C and 60°C under slight stirring.

[0052] The ultrasonic technique involves the sonication, at temperatures between 0°C and 60°C, of ​​a dispersion obtained by mixing an organic phase containing surfactants with an aqueous phase containing plant extracts.

[0053] These and other methods for preparing compositions containing niosomes are described in the literature, for example in the article "Niosomes: a novel drug delivery system" by Madhav et al.; International journal of research in pharmacy and chemistry, IJRPC 2011, 1 (3), 498-5.11.

[0054] The niosome dispersion / solution of the present invention preferably comprises the amounts of ingredients set out below, expressed as weight percentages (% w / w) relative to the total weight of the niosome dispersion / solution.

[0055] Cannabidiol is included in the niosome dispersion / solution in an amount of up to 10% w / w. Preferably, cannabidiol is present in an amount ranging from 1% to 8% w / w, more preferably from 2% to 7% w / w, even more preferably from 3% to 6% w / w. Advantageously, the amount of cannabidiol is in the range of 4% to 5% w / w.

[0056] The dispersion / niosome solution comprises the polyglycerol ester in an amount in the range of 40% to 90% w / w, preferably in the range of 50% to 80% w / w.

[0057] The amount of β-glucan contained in the niosome dispersion / solution is in the range of 1% to 5% w / w, preferably 1% to 3% w / w.

[0058] The amount of glycol contained in the niosome dispersion / solution is in the range of 0.1% to 5% w / w, preferably 0.5% to 3% w / w.

[0059] The resulting niosome dispersion / solution contains water in an amount of 10% to 40% w / w, preferably 20% to 30% w / w.

[0060] The niosome dispersion / solution may contain other ingredients such as stabilizers and preservatives in amounts up to 1% w / w.

[0061] The topical compositions of the present invention may be liquid or semi-solid.

[0062] In particular, the topical compositions of the present invention are cosmetic compositions and / or medical devices and / or pharmaceutical preparations for application to the skin, epithelia and mucous membranes.

[0063] The topical composition of the present invention advantageously comprises a liquid or semi-solid composition in which the aqueous niosome composition is dispersed in an amount of 0.5% to 10% by weight, preferably 1% to 5% by weight, relative to the total weight of the topical composition.

[0064] Liquid compositions of the present invention include solutions, emulsions, microemulsions, lotions, gels, foams, milks, micellar waters, oils, tensiolites or suspensions with a wide range of viscosity variations.

[0065] Liquid compositions include, for example, aqueous solutions, hydroalcoholic solutions, oily solutions, emulsions obtained by dispersing an oily phase in an aqueous phase (oil-in-water type) or vice versa by dispersing an aqueous phase in an oily phase (water-in-oil type), as well as suspensions obtained by dispersing a dispersed phase consisting of solid particles in a dispersion medium generally represented by an aqueous or oily liquid of a particular viscosity.

[0066] Semi-solid compositions of the present invention include creams, gels, balms, ointments, pastes, cream gels, sticks, and waxes.

[0067] Additionally, the topical compositions of the present invention may contain various topically acceptable additives or vehicles known to those skilled in the art that are useful in the preparation of cosmetics and / or medical devices and / or pharmaceutical formulations, such as emulsifiers, humectants, solvents, emollients, stabilizers, thickeners, preservatives, lubricants, sequestering or chelating agents, fillers, powders, fragrances, perfumes, absorbents, colorants and opacifiers, antioxidants, vitamins, natural extracts, polysaccharides, shielding substances, UV filters, essential oils, keratin actives, and amino acids.

[0068] Suitable solvent additives include, for example, water, alcohols, ketones (such as acetone and methyl isobutyl ketone), glycols (such as ethylene glycol, propylene glycol and butylene glycol), polyethylene glycols (such as PEG-40, PEG-50, PEG-60), alkyl acetates (such as amyl acetate, isopropyl acetate, butyl acetate), paraffins and isoparaffins, cycloalkyls (such as cyclohexane), glycerin, natural and synthetic oils, natural and synthetic triglycerides, and essential oils.

[0069] Advantageously, the topical composition of the present invention is an aqueous composition.

[0070] In aqueous compositions, water represents the main component of the composition and may even amount to up to 99% by weight relative to the weight of the total composition. Aqueous compositions preferably contain water in an amount ranging from 25% to 99% by weight, preferably from 35% to 95% by weight, more preferably from 50% to 90% by weight relative to the weight of the total composition.

[0071] The aqueous compositions of the present invention may contain a total amount of non-aqueous solvents preferably in the range of about 0.1% to about 60% by weight, more preferably 1% to 40% by weight, and even more preferably 5% to 35% by weight, based on the weight of the total composition.

[0072] Suitable emulsifying additives include nonionic, cationic, anionic and amphoteric surfactants, or their combinations.The emulsifiers useful in the present invention include sorbitan, ethoxylated long-chain alcohols, alkyl polyglycosides, soaps, alkyl sulfates such as sodium cetylstearyl sulfate, mono- and di-alkyl phosphates, alkyl sulfonates, hydrogenated castor oil, acyl isothionates, sucrose esters, betaine, lecithin, quaternary ammonium salts, alkyl oleates, glycerides such as caprylocaproyl polyoxylglycerides, and emulsifiers from olive oil.

[0073] Preferably, the compositions of the present invention comprise a total amount of emulsifiers ranging from about 0.1% to about 60% by weight, more preferably from 0.5% to 25% by weight, and even more preferably from 0.5% to 10% by weight, based on the weight of the total composition.

[0074] Typical viscosity additives useful in the present invention are, for example, xanthan gum, hydroxypropyl cellulose, hydroxyethyl cellulose, carbopol, carrageenan, poloxamers, and acacia gum.

[0075] Advantageously, the compositions of the present invention comprise a total amount of thickeners ranging from about 0.1% to about 25% by weight, more preferably from 0.5% to 10% by weight, and even more preferably from 0.5% to 5% by weight, relative to the weight of the total composition.

[0076] Examples of moisturizing additives useful in the present invention include urea, allantoin, hyaluronic acid and its derivatives, glycerin, amino acids, acetyl monoethanolamide, butoxypropanol, butyl glycol, low molecular weight polyethylene glycols (e.g., PEG-40, PEG-50, PEG-60), aloe, mallow, trehalose, and sorbitol.

[0077] Preferably, the compositions of the present invention comprise a total amount of humectant in the range of about 0.05% to about 25% by weight, more preferably 0.5% to 10% by weight, and even more preferably 0.1% to 5% by weight, based on the weight of the total composition.

[0078] Examples of suitable emollient additives useful in the present invention include, for example, lanolin, almond oil, olive oil, vegetable oils, jojoba oil, argan oil, hydrogenated castor oil, natural lipophilic extracts, microcrystalline wax, polydimethylsiloxane (dimethicone), polymethylphenylsiloxane, glycol and silicone polymers, mineral oil, paraffin, ozokerite, ceresin, triglyceride esters, acetylated monoglycerides, ethoxylated glycerides, alkyl esters of fatty acids, fatty acids, fatty acids, long chain alcohols, sterols, beeswax, polyhydric alcohols, polyesters, and fatty acid amides.

[0079] Preferably, the compositions of the present invention comprise a total amount of emollients ranging from about 0.1% to about 25% by weight, more preferably from 0.5% to 10% by weight, and even more preferably from 0.5% to 5% by weight, based on the weight of the total composition.

[0080] Examples of fragrances useful in the present invention are natural essential oils or fractions or concentrates of essential oils, such as lemon oil, bergamot oil, lavender oil, limonene, linalool, etc. Preferably, the compositions of the present invention contain a total amount of fragrance in the range of about 0.001% to about 0.1%.

[0081] Examples of suitable preservative additives useful in the present invention include, for example, alcohols such as ethanol, phenoxyethanol, and benzyl alcohol, methyl and propyl parahydroxybenzoate, butylated hydroxyanisole (BHA), sorbates, urea derivatives, and isothiazolinones, such as ascorbic acid and derivatives, tocopherol and derivatives, and natural preservatives such as polyphenols. Further examples of dyes that can be used in the topical compositions of the present invention can be found in Annex V of Regulation (EC) No. 1223 / 2009 of November 30, 2009.

[0082] Preferably, the compositions of the present invention comprise a total amount of preservatives ranging from about 0.01% to about 2.00%, more preferably 0.05% to 1.00%, and even more preferably 0.1% to 0.5% by weight, based on the weight of the total composition.

[0083] Examples of sequestering or chelating agents useful in the present invention are EDTA, HEDTA, alkyl oxalates, lithium or potassium oxalate, sodium or potassium pyrophosphate. Preferably, the compositions of the present invention contain a total amount of sequestering or chelating agents ranging from about 0.01% to about 20% by weight, more preferably 0.05% to 10% by weight, and even more preferably 0.1% to 5% by weight, based on the weight of the total composition.

[0084] Examples of suitable stabilizing additives useful in the present invention are long chain alcohols (e.g., cetyl alcohol, stearyl alcohol) and mixtures thereof, high molecular weight polyethylene glycols (e.g., PEG-9000 and PEG 14000), and polyvinylpyrrolidones (e.g., povidone).

[0085] Preferably, the compositions of the present invention comprise a total amount of stabilizer in the range of about 0.1% to about 25% by weight, more preferably 0.5% to 15% by weight, and even more preferably 1% to 10% by weight, based on the weight of the total composition.

[0086] Examples of suitable powder additives useful in the present invention are elastomeric silicones such as dimethicone / vinyl dimethicone crosspolymer (DC 9506, Dow-Corning), a mixture of cyclomethicone and dimethicone crosspolymer (DC 9040, Dow-Corning), silica-treated crosspolymer of dimethicone and vinyl dimethicone (DC 9701, Dow Corning), a mixture of cyclomethicone and dimethicone / vinyl dimethicone crosspolymer (SFE 839, GE Bayer Silicones).

[0087] Preferably, the compositions of the present invention contain a total amount of powder additives ranging from about 0.1% to about 5% by weight, more preferably from 0.2% to 1% by weight, based on the weight of the total composition.

[0088] Examples of opacifying agents useful in the present invention are zinc or aluminum oxide, titanium or zinc dioxide, alumina, mica, fatty acid salts with aluminum, and gypsum.

[0089] Examples of dyes that are preferably used in the present invention are water-soluble dyes that do not stain the skin, leave no residue, and are easily washed off, such as Acid Blue 3 CI 42051, Acid Blue 9 CI 42090, Acid Blue 74 CI 73015, Pigment Blue 15 CI 74160, Acid Yellow 3 CI 47005, Food Yellow 3 CI 15985, Acid Yellow 23 CI 19140, Acid Yellow 73 CI 45350, Acid Red 14 CI 14720, Acid Red 18 CI 16255, Acid Red 27 CI 16185, Acid Red 51 CI 45430, Acid Green 1 CI 10020, Acid Green 25 CI 61570, and mixtures thereof. Further examples of dyes that can be used in the topical compositions of the present invention can be found in Annex IV of Regulation (EC) No. 1223 / 2009 of 30 November 2009.

[0090] Preferably, the compositions of the present invention comprise opacifiers and colorants in a total amount ranging from about 0.01% to about 15% by weight, more preferably from 0.05% to 5% by weight, based on the weight of the total composition.

[0091] Preferably, the composition of the present invention can contain UV filters that can shield skin from the effects of ultraviolet radiation.Examples of UV filters include acrylates such as 2-ethylhexyl 2-cyano-3,3-diphenylacrylate (PARSOL 340) and ethyl 2-cyano-3,3-diphenylacrylate, camphor derivatives such as camphor 4-methylbenzylidene (PARSOL 5000) and camphor 3-benzylidene, cinnamates such as octyl methoxycinnamate (PARSOL MCX), ethoxyethyl methoxycinnamate, diethanolamine methoxycinnamate (PARSOL Hydro), triazone derivatives such as ethylhexyl triazone (UVINUL T-150), diethylhexyl butamido triazone (UVASORB HEB), 4-tert-butyl-4'-methoxydibenzoylmethane (PARSOL 1789), dibenzoylmethane derivatives such as dimethoxydibenzoylmethane, benzotriazole derivatives such as 2,2'-methylene-bis-(6-(2H-benzotriazol-2-yl)-4-(1,1,3-tetramethylbutyl)-phenol (TINOSORB M), triazine derivatives such as bis-ethylhexyloxyphenol methoxyphenyl triazine (TINOSORB S). Other examples of UV filters that can be used in the topical compositions of the present invention can be found in Annex VI of Regulation (EC) No. 1223 / 2009 of 30 November 2009.

[0092] Preferably, the compositions of the present invention comprise a total amount of UV filters ranging from about 0.1% to about 20% by weight, more preferably from 0.5% to 15% by weight, based on the weight of the total composition.

[0093] The following experimental section illustrates at least one embodiment of the present invention, but does not in any way limit the scope of protection defined in the claims attached to this description. [Example]

[0094] Example 1 - Preparation of niosomes A niosome dispersion containing cannabidiol (CBD) (CBD-S5) was prepared according to the composition shown in Table 1 below. The resulting composition had the appearance of a homogeneous, pale yellow, viscous gel. The weight percentage of each component relative to the weight of the total composition is expressed. [Table 1]

[0095] [Example 2] The vesicle morphology of the niosome dispersion (CBD-S5) of Example 1 was examined with a TEM transmission electron microscope (JEM-1200EX, JEOL Co., Tokyo, Japan) using the negative staining method.

[0096] A small aliquot (5.0 ml) of the CBD-S5 dispersion was centrifuged at 4°C at a speed of approximately 80,000 x g for 30 minutes. The pellet was dried and then diluted with 1% uranyl acetate solution. A drop of the suspension was directly used to load onto a carbon-coated electron microscope screen. Excess sample was removed by absorbing with plain filter paper. The screen thus prepared was incubated at 30°C for 10 minutes to completely dry it and then observed by TEM at 80 kV. A micrograph of the observed vesicles is shown in Figure 1. The numbered vesicles had the diameters shown in Table 2 below. [Table 2]

[0097] Ultrastructural analysis by transmission electron microscopy showed the presence of spheroidal vesicle structures with an average size of approximately 200 nm.

[0098] Figure 2 shows a dynamic light scattering (DLS) graph obtained by analyzing the same CBD-S5 sample using a Brookhaven 90Plus Particle Size Analyzer, which determined a mean diameter of 190.4 nm and a polydispersity index of 0.137.

[0099] [Example 3] Elasticity is one of the most important characteristics of niosomes. Elasticity is estimated by extrusion measurements. Vesicles of the niosome dispersion (CBD-S5) of Example 1 were extruded under constant pressure through a polycarbonate filter with a pore size of 100 nm. The elastic modulus is expressed as the deformability index (D), which is calculated using the following formula: D=J×(rv / rp)2 where J is the fraction of the suspension extruded in 5 minutes, rv is the size of the vesicles after passing through the filter as measured by DLS, and rp is the pore size of the filter.

[0100] Good deformability is indicated by a deformability index greater than 80. Testing was carried out using an Avestin LiposoFast instrument and by measuring particles on a Brookhaven 90Plus-Particle Size Analyzer.

[0101] The results showed a 5-minute extrusion suspension ratio (J) of 87% with an RV vesicle size of 141 nm. The deformability index (D) was therefore 172.96, confirming the excellent deformability of niosomes, a characteristic that predicts their excellent ability to penetrate skin, epithelia, and skin appendages. The properties of elasticity and deformability are essential for interaction with the superficial layers of skin and skin appendages, facilitating absorption and permeation, not just via chemical interactions.

[0102] [Example 4] Niosome-dispersed vesicles from Example 1 (CBD-S5) and a 5% solution of cannabidiol in MCT (CBD-5%) were evaluated for their ability to diffuse through an artificial membrane, using phosphate-buffered saline (PBS) as a negative control. Medium-chain triglyceride oil (MCT), used for comparison, is among the most common cannabidiol solubilization systems, even for topical use.

[0103] The assay involved the assessment of cannabidiol diffusion through a Strat-M® artificial membrane (Sigma-Aldrich) used in transmembrane diffusion studies using a Franz cell, which simulates the diffusion of various types of compounds and formulations in human epidermis.

[0104] The artificial Strat-M® membrane consists of two layers of polyethersulfone (PES, more diffusion-resistant) and a polyolefin layer (more diffusion-resistant) placed on the surface. These polymer layers create a porous structure with a diffusion gradient. Additionally, this porous structure is impregnated with a mixture of synthetic lipids, which gives it skin-like properties.

[0105] The diffusion cell consists of a donor chamber and a receptor chamber with a membrane between them. The receptor chamber contains phosphate buffer containing 5% bovine serum albumin (BSA) and a magnet for sufficient mixing of the solution. The sample application area is 0.2 cm. 2 is.

[0106] The CBD-S5 and CBD-5% samples were applied to the membrane using a Gilson P100 positive displacement pipette specially designed for high density liquids (1 g / cm 2 The negative control was a membrane treated with phosphate-buffered saline (PBS) alone.

[0107] Samples and controls were incubated at 32°C and 5% CO2 for 16, 24, and 48 hours of exposure. Samples were tested in triplicate. At different exposure times, aliquots of receptor fluid were withdrawn with a syringe. The samples thus collected were immediately frozen at -20°C and subsequently thawed for quantitative chromatographic analysis.

[0108] An aliquot of the amount of the solution that had diffused under the membrane at each evaluation time point was diluted with a methanol solution acidified with 0.3% phosphoric acid (v / v). The supernatant was analyzed by HPLC-DAD using a WATERS 2695 instrument under the following analytical conditions: Wavelength: 212nm Injection volume: 10μl Column: Eclipse XDB-C18 3.5pm 3.0x150mm Column temperature: 35℃ Flow rate: 0.6ml / min Mobile phase A: 0.3%H3PO4 in H2O milliQ Mobile phase B: 0.3% H3PO4 in ACN Gradient: As per Table 3 [Table 3]

[0109] The results are summarized in Table 4 below. [Table 4]

[0110] The results in Table 4 demonstrated a significant increase in cannabidiol diffusion for the CBD-S5 sample of the present invention compared to the CBD-5% sample.

[0111] The results of the test can predict an improved ability to penetrate and release the active ingredient into the skin.

[0112] [Example 5] The irritation potential of the niosome dispersion of Example 1 (CBD-S5) was evaluated by in vitro testing on reconstructed epidermis and in vivo testing on a group of 20 subjects.

[0113] Determining whether topical products and cosmetics are irritants is an important evaluation for establishing procedures for correct and safe use.

[0114] A. In Vitro Testing The in vitro test consists of topical exposure of the test substance to reconstituted human epidermis (RHE) followed by cell viability testing.

[0115] Cell viability is determined by the conversion of MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) to formazan blue salt, which is quantitatively measured after extraction from tissue. Conversion occurs via the mitochondrial enzyme succinate dehydrogenase, active only in viable cells, which opens the tetrazole ring of MTT to form formazan. Evaluation of the viability of tissues exposed to a test substance compared with a negative control (treated with Dulbecco's phosphate-buffered saline—DPBS) and a positive control (treated with sodium dodecyl sulfate—SDS) is used to predict skin irritation.

[0116] The reconstituted human epidermis model consists of normal human-derived epidermal keratinocytes cultured to recreate a highly differentiated, multilayered human epidermis, consisting of a basal layer, a spinous layer, and a granular layer, as well as a multilayered stratum corneum containing intercellular lamellar lipid layers arranged similarly to that present in vivo.

[0117] The reconstructed skin sample was 0.63 cm 2 The test is performed in triplicate. Each sample is treated with 25 μg of CBD-S5. In parallel, a positive control (PC) test is performed by applying 30 μL of 5% SDS solution to the skin sample, and a negative control (NC) test is performed by applying 30 μL of DPBS to the skin sample. The treatment takes 60 minutes, after which the samples are washed to remove the test substance and incubated for 24 hours before performing the MTT assay.

[0118] The MTT assay is performed by transferring samples to a 24-well plate containing MTT solution (1 mg / ml). The blue formazan salt produced by cellular mitochondria is extracted with 2.0 ml of isopropanol per sample.

[0119] The optical density of the extracted formazan was determined spectrophotometrically at a wavelength of 570 nm using a pQUANT BIO TEK Microplate Spectrophotometer. Relative cell viability was calculated for each tissue as a percentage of the mean optical density for the negative control tissue. The results are summarized in Table 5 below and Figure 3. [Table 5]

[0120] Thus, the niosome dispersion from Example 1 (CBD-S5) was found to be non-irritating.

[0121] B. In Vivo Testing The in vivo test consisted of applying the niosome dispersion (CBD-S5) from Example 1 to the back and / or forearms of selected subjects using a Finn chamber (20 microliter capacity cell). The irritation of the product was evaluated by testing at three separate time points. Immediate skin irritation was evaluated by applying the product for 60 minutes (T1). Skin irritation was evaluated by applying the product for 48 hours (T2) and 24 hours after removing the product (T3). The evaluation was divided into four levels of irritation, as described in Table 6 below. [Table 6]

[0122] Table 7 below summarizes the results obtained for the subjects studied at the end of the study. [Table 7]

[0123] In vivo testing confirmed the non-irritating properties of the niosome dispersion of Example 1 (CBD-S5).

[0124] Example 6 - Antimicrobial Resistance Test (Challenge Test) The test consists of "challenging" the preparation with a specified inoculum of the appropriate microorganism, leaving the inoculated preparation at a predetermined temperature, and removing samples from the container at specified time intervals and counting the number of organisms present in the samples taken.

[0125] The tests were carried out according to the recommendations of the Italian Pharmacopoeia - IXth edition and the equivalent European Pharmacopoeia 5.1.3, using bacterial cultures of the following microbial strains: ·Pseudomonas aeruginosa ATCC 9027 Escherichia coli ATCC 8739 ·Staphylococcus aureus ATCC 6538 Candida albicans ATCC 10231 ·Aspergillus brasiliensis ATCC 16404

[0126] The niosome dispersion of Example 1 (CBD-S5) contained 10 5 ~10 6 Inoculum containing 10 4 ~10 5 Various microorganisms were inoculated using an inoculum containing a number of fungi or yeasts. The inoculated products were stored at room temperature (20-25°C) away from light. Samples of the products were taken at time t0 (baseline) and at intervals of 2 (t2), 7 (t7), 14 (t14), and 28 (t28) days to determine the number of microorganisms present.

[0127] The results are summarized in Table 8 below, which shows the values ​​found for each microorganism, expressed on a logarithmic basis, at various observation times. The data represent colony forming units (cfu) per gram of product. [Table 8]

[0128] Based on the results obtained, the niosome dispersion of Example 1 (CBD-S5) passed the challenge test and showed inhibitory activity against all microorganisms according to the acceptance criteria (CTFA M-3 and M4, ISO 11930:2012, and Ph Eu 5.3.1), giving a 99.9% reduction of inoculated bacteria and a 90% reduction of molds or fungi within 7 days of inoculation, with further reduction in subsequent periods.

[0129] Example 7 - Stability testing by accelerated aging The niosome dispersion of Example 1 (CBD-S5) was subjected to a series of stability and accelerated aging tests under different conditions. (A) Exposed to light at room temperature (25°C) for 90 days (B) 40℃ for 90 days (C) 4℃ for 90 days (D) Heat shock: 15 days at 4°C, 15 days at 40°C (3 cycles)

[0130] Parameters of interest (appearance, color, pH, density) were monitored biweekly for a total of 90 days.

[0131] The results are summarized in Table 9 below. [Table 9]

[0132] After 90 days of accelerated aging under various stress conditions, product parameters, particularly density as an indicator of niosome vesicle stability, did not change significantly, except for the color, which changed from yellow to red. This change is due to the known instability of cannabidiol to heat and light. Storage conditions for niosome preparations include light- and air-impermeable packaging and keeping them at room temperature.

[0133] Example 8 - Microparticle resistance and cell viability test The study involved treating reconstituted human epidermal (RHE) tissue, either protected or unprotected with the niosome dispersion (CBD-S5) from Example 1, with a particulate sample having an aerodynamic diameter of less than 2.5 μm (PM2.5), chosen to represent ambient particulate pollution. In parallel, reconstituted human epidermal tissue was treated with Dulbecco's phosphate buffered saline (DPBS—negative control NC), sodium dodecyl sulfate (SDS—positive control PC), and the niosome dispersion (CBD-S5) from Example 1 alone.

[0134] Specifically, (1) 30 μl DPBS (NC), (2) 30 μl SDS 5% (PC), (3) 20 μg PM2.5 dissolved in 30 μl PBS, (4) 30 μl CBD-S5, and (5) RHE (EpiDerm) treated with 30 μl CBD-S5 containing 20 μg PM2.5. TM EPI-200, MakTek Corporation) was cultured in its own culture medium (EpiDerm TM Wells containing EPI-100-NMM (MakTek Corporation) were set up in triplicate.

[0135] After 24 h of incubation at 37°C in a 5% CO2 controlled atmosphere, cell viability of the RHE samples was assessed by MTT assay as described in Example 5A, while the medium was collected and analyzed for IL-1α release by ELISA assay using the EMIL1ALPHA kit (Invitrogen-Thermo Scientific) as follows.

[0136] 100 μl of medium from each treatment was transferred to anti-human IL-1α-coated wells and incubated for 2 hours at room temperature. At the end of the incubation, the medium was removed and the wells were washed four times with 1X Wash Buffer. 100 μL of biotinylated antibody was added to each well and incubated for 1 hour at room temperature. Finally, the wells were washed four times with 1X Wash Buffer, treated with 100 μl of streptavidin-HRP solution for 45 minutes at room temperature, and finally washed four times with 1X Wash Buffer. 100 μl of TMB substrate was added to each well and incubated for 10 minutes in the dark. Finally, 100 μl of stop solution was added to each well, and spectrophotometric measurements were taken at wavelengths of 450 nm and 550 nm using a pQUANT BIO TEK Microplate Spectrophotometer.

[0137] The change in IL-1α levels released from RHE tissue after each treatment was expressed as a percentage compared to untreated RHE (NC) (100%) used as a control. Table 10 below summarizes the results of the study, which are also shown in Figures 4 and 5. [Table 10]

[0138] In vitro MTT tests showed that PM2.5 reduced cell viability to 28.51%, while co-treatment with CBD-S5 protected reconstituted human epidermis (RHE) against the toxic effects of PM2.5. The data showed that CBD-S5 was able to increase cell viability from 28.5% to 71.25%. At the same time, the results of the CBD-S5-only test surprisingly showed an increase in cell viability over the control, up to 110.86%, thus demonstrating remarkable regenerative activity. It is believed that this increase may be due to the regenerative effect brought about by the presence of the polysaccharide β-glucan.

[0139] ELISA assays showed that (i) PM2.5 at a concentration of 20 μg / well induced an increase in IL-1α release, and (ii) treatment with CBD-S5 was able to reduce IL-1α release in both untreated and 20 μg / well PM2.5-treated tissues. Again, a striking reduction in IL-1α release was observed in samples treated with CBD-S5 alone, thus demonstrating significant anti-inflammatory activity.

[0140] Example 9 - In vitro evaluation of sedative activity A multi-layer in vitro skin cell model was used to quantitatively evaluate the effect of the samples in protecting skin cells and inhibiting the sedative response caused by a mild irritant such as sodium lauryl sulfate (SLS).

[0141] The inhibition of SLS-induced IL-1α cytokine release was investigated (through a specific ELISA assay) after exposure to the test substances and on untreated samples of skin. Cell viability was determined by MTT assay.

[0142] Both assays used a reconstituted artificial human skin model containing normal human epidermal keratinocytes, grown as an integrated three-dimensional cell culture model, which fully mimics human skin in vitro. This model exhibits normal barrier function (presence of a well-differentiated stratum corneum). This model was supplied by Episkin (Lion, Batch 20-RHE-041).

[0143] The epidermis was treated with 0.30% SLS for 70 minutes to induce the synthesis and release of IL-1α. Then, 40 μl of the niosome dispersion (CBD-S5) of Example 1 (diluted to 2% in sterile water) was applied to two epidermis and exposed to 37°C and 5% CO2 for 24 hours. As a negative control, two epidermis units were treated with phosphate buffer, while an epidermis unit treated with 0.30% SLS for 70 minutes was used as a positive control. The test was performed in duplicate.

[0144] At the end of the exposure period, samples were removed by phosphate buffer solution washing (PBS) and an MTT assay was performed to assess cell viability.

[0145] The epidermal units were treated with 1 mg / ml MTT solution (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide) at 37°C for 3 hours. The solution was then removed and replaced with isopropanol and incubated for an additional 2 hours at room temperature. Two aliquots of each sample were transferred to a 96-well plate for reading. Optical density (OD) readings were taken at a wavelength of 570 nm using a colorimeter (Tecan model Infinite F200) equipped with a microplate reader.

[0146] The results were expressed as percent cell viability and % relative protection, which were obtained using the following formula: % cell viability (cv)=[OD 570 TS / OD 570 NC] x 100 %Relative Protection = (%cvTS-%cvPC) / (%cvNC-%cvPC)

[0147] The results are summarized in Table 6 below. [Table 11]

[0148] Culture medium was collected at 6 and 24 hours for IL-1α assay. A unit of culture medium treated with PBS was used as a negative control, while two units of culture medium treated with 0.30% SLS were used as a positive control. IL-1α was determined in the medium of treated and untreated epidermis using a direct ELISA test (enzyme-linked immunosorbent assay). The colorimetric signal was directly proportional to the amount of cytokine in the medium. Samples were read at 450 nm. The sensitivity limit was less than 10 pg / ml.

[0149] Cytokine concentrations were determined using a standard curve. Results were expressed as percent inhibition of IL-1α release, obtained by the following formula: % IL-1α inhibition = 100 - (pg / ml IL-1α release test sample / pg / ml IL-1α positive control) * 100

[0150] The results are summarized in Table 7 below. [Table 12]

[0151] The data summarized in Tables 6 and 7 demonstrate that CBD-S5 was able to protect skin cells and inhibit the release of IL-1α, thus demonstrating in vitro soothing activity.

[0152] Example 10 - Mitosis in hair bulb cells The purpose of this assay was to quantitatively evaluate the effect of CBD-S5 on stimulation of cell cycle and total protein synthesis in human hair dermal papilla fibroblasts by cell viability assay after starvation (MTT), as well as total protein extraction and quantification at different exposure times during continuous administration at toxic levels. If a composition is able to increase cell proliferation and protein synthesis, this suggests a role in stimulating follicle growth and the early phase of tissue regeneration.

[0153] This test is performed on human hair dermal papilla cells (HHDPCs), which have a fibroblast-like morphology.

[0154] Cells were cultured in MEM containing 10% FBS and antibiotics. Cells were seeded into 24-well plates and grown at 37°C and 5% CO2 for 24 hours. Cells were starved in serum-free medium for 6 hours before treatment. Fresh medium without serum and supplemented with serial dilutions (0.006 and 0.003 mg / ml) of the niosome dispersion (CBD-S5) of Example 1 was then added to the cells. The niosome dispersion was dissolved directly in the culture medium. Tests were performed in triplicate.

[0155] After 24 and 48 h of exposure, cell viability and total cellular protein were assessed in separate plates. Untreated cells served as a negative control (NC), and cells treated with human insulin served as a positive control (PC).

[0156] Cell viability was assessed by incubating the tissue with MTT (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide) solution for 2 hours. The precipitated formazan was then extracted with DMSO and quantified spectrophotometrically. The optical density at 570 nm (OD570) was measured using a microplate reader (Tecan, Infinite 200 PRO), and the background at 650 nm (OD650) was subtracted.

[0157] Cell viability was expressed as a percentage according to the following formula: %Cell Viability=[(OD 570 -OD 650 ) Test product / (OD 570 -OD 650 )NC]×100

[0158] The results are summarized in Table 8 below. [Table 13]

[0159] Total cellular protein was assayed according to the Bradford method. At the end of the treatment, cells were washed twice with PBS and lysed by treatment with purified water at 4°C. A dye reagent was added to each sample. A titrated standard curve was established with a concentration range of 2-12 μg / ml. 200 μl of each sample, control, and standard was transferred to a 96-well plate. Readings were taken at 595 nm using a colorimeter equipped with a plate reader.

[0160] To quantify protein, a standard plot using albumin was designed, and the sample concentrations were determined based on their absorbance values ​​using an interpolated plot formula. The average value of each set of data was calculated, and the percent increase in protein synthesis was determined for each sample compared to the negative control (NC) according to the following formula: % Increase in protein synthesis = (µg / ml protein sample / µg / ml NC) * 100

[0161] The results are summarized in Table 9 below. [Table 14]

[0162] The data summarized in Tables 8 and 9 demonstrate that CBD-S5 was able to stimulate cell proliferation and protein synthesis in human hair dermal papilla fibroblasts at a concentration of 0.003 mg / ml compared to untreated control cell cultures (negative control) after a 48 hour exposure period.

[0163] Example 11 - Anti-itch activity In vivo, IgE-mediated degranulation of basophil cells induces an immediate allergic response characterized by the rapid release of pre-stored inflammatory mediators (histamine, leukotrienes, thromboxane, basophil enzymes, hexosaminidase), resulting in redness, rash, itching, and a local inflammatory response. The ability of a composition to inhibit basophil cell degranulation is indicative of its ability to inhibit the above symptoms, primarily itching.

[0164] The test was performed using a transfected rat basophil cell line (RBL-2H3 ATCC 94144) expressing the IgE human receptor (FcRI). (R) CRL-2256 TM ) Cells are maintained in RPMI containing 10% FCS and 2 mM glutamine.

[0165] Untreated cells were used as a negative control for spontaneous degranulation.

[0166] A positive control consisting of cells exposed to anti-human IgE receptor antibody was used to assess the maximum degranulation level.

[0167] Cell lysates in 1% Triton were also analyzed to assess the maximum possible release of the analyzed molecules.

[0168] To evaluate the effect of the niosome dispersion of Example 1 (CBD-S5) on basophil degranulation, samples were pre-incubated with a transfected rat basophil (RBL) cell line expressing the human receptor for IgE (FcRI).

[0169] The release of β-hexosaminidase during degranulation was monitored in RBL-SX38 cell supernatants incubated with p-nitrophenyl-N-acetyl-pD-glucosamine (Sigma-Aldrich) in 0.1 M citrate buffer (pH 6.2) for 120 min at 37°C. The reaction was stopped with 0.1 M carbonate buffer (pH 10), and the absorbance was read at 405 nm (OD ). 405 ).

[0170] Supernatant from untreated cells was used as a negative control. Maximal stimulation of RBL-SX38 was assessed in 1% Triton X-100 lysates of cell monolayers.

[0171] The optical densities of the negative and positive controls and the Triton X-100 lysates are reported in Table 10 below. [Table 15]

[0172] The niosome dispersion of Example 1 (CBD-S5) was solubilized in cell culture medium at different concentrations as shown in Table 11 below.

[0173] Serial dilutions of sodium hyaluronate, as shown in Table 11 below, were also used as a control for inhibition of basophil degranulation.

[0174] Optical density (OD) measured at 405 nm 405 ) are reported in Table 11 below. [Table 16]

[0175] The percentage of inhibition of degranulation of activated basophils bearing IgE receptors was calculated using the following formula: % degranulation inhibition=100-[(OD 405 CBD-S5+PC - OD 405 NC) / (OD 405 PC-OD 405 NC)]*100

[0176] The results are shown in Table 12 below. [Table 17]

[0177] The niosome dispersion (CBD-S5) was able to inhibit basophil degranulation in a dose-dependent manner. The strongest effect was observed at the highest concentration tested. No interference with spontaneous degranulation was detectable.

[0178] The above results demonstrated that the niosome dispersion (CBD-S5) has anti-itch activity.

Claims

1. 1. A topical composition comprising an aqueous composition comprising cannabinoids in niosomes having a size of less than 500 nm and at least one topically acceptable excipient, wherein the niosomes comprise: (i) at least one linear or branched polyglycerol esterified with a saturated linear fatty acid or a monounsaturated linear fatty acid; (ii) at least one polysaccharide selected from the group consisting of pullulan, glucan, alginate, amylose, glycogen, and inulin; and (iii) at least one glycol having 4 to 16 carbon atoms.

2. 10. The topical composition of claim 1, wherein the cannabinoid is of natural or synthetic origin.

3. The topical composition of claim 1, wherein the cannabinoid is selected from the group consisting of cannabidiol, cannabigerol, and cannabinol.

4. 2. The topical composition of claim 1, wherein the polysaccharide is selected from the group consisting of α-glucan and β-glucan.

5. 2. The topical composition of claim 1, wherein the linear or branched polyglycerol is selected from the group consisting of triglycerol, tetraglycerol, hexaglycerol, octaglycerol, and decaglycerol.

6. 2. The topical composition of claim 1, wherein the saturated straight chain fatty acid or monounsaturated straight chain fatty acid is selected from the group consisting of monocarboxylic acids having from 4 to 32 carbon atoms.

7. 2. The topical composition of claim 1, wherein the saturated straight chain fatty acid is selected from the group consisting of butyric acid, valeric acid, caproic acid, enanthic acid, caprylic acid, pelargonic acid, capric acid, lauric acid, myristic acid, palmitic acid, margaric acid, stearic acid, arachidic acid, behenic acid, lignoceric acid, cerotic acid, montanic acid, melissic acid, and lacteric acid.

8. 2. The topical composition of claim 1, wherein the monounsaturated straight chain fatty acid is selected from the group consisting of myristoleic acid, palmitoleic acid, oleic acid, gadoleic acid, and erucic acid.

9. The topical composition of claim 1, wherein the polysaccharide is a β-glucan.

10. 2. The topical composition of claim 1, wherein the glycol having 4 to 16 carbon atoms is selected from the group consisting of 1,2-butanediol, 1,2-pentanediol, 1,2-hexanediol, 1,2-heptanediol, 1,2-octanediol (caprylyl glycol), 1,2-decanediol (capryl glycol), 1,2-dodecanediol (lauryl glycol), and 1,2-hexadecanediol.

11. 1. An aqueous composition comprising cannabidiol incorporated into niosomes, characterized in that the niosomes comprise: (i) at least one linear or branched polyglycerol esterified with a saturated linear fatty acid or a monounsaturated linear fatty acid; (ii) at least one polysaccharide selected from the group consisting of pullulan, glucan, alginate, amylose, glycogen, and inulin; and (iii) at least one glycol having from 4 to 16 carbon atoms.

12. The composition of claim 11 , wherein the composition is an aqueous solution or dispersion.

13. 13. A method for producing the aqueous composition of claim 11 or 12, comprising the use of hand shaking or ultrasonic shaking techniques.

Images